AstraZeneca explores tie-up with Bristol Myers Squibb
AstraZeneca has been exploring a possible combination with US rival Bristol Myers Squibb after holding discussions in recent months, people familiar with the matter said. A deal would join companies valued at about £196bn for AstraZeneca and roughly $133bn for Bristol Myers Squibb, creating one of the world's biggest pharmaceutical groups. Talks could lead to a near-term agreement but also might be delayed or fall apart. The move would extend AstraZeneca's pivot toward the US market, following its elevation of a New York listing in June, and could have broad industry and market consequences.
AstraZeneca has held merger talks with Bristol Myers Squibb.
Context
The companies held discussions about a tie-up in recent months. A deal could be agreed, delayed, or fall apart. AstraZeneca raised its New York listing in June as part of a US market pivot.
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorLocked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsLocked
- Probability of ChangeLocked
- Debate PointsLocked
- Prerequisite KnowledgeLocked
- Follow-up QuestionsLocked
- Pros & ConsLocked